The role of endoscopic ultrasound (EUS) in relation to other imaging modalities in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and ductal pancreatic adenocarcinoma

Julio Iglesias-García1, Björn Lindkvist2, José Lariño-Noia1 and J. Enrique Domínguez-Muñoz1

1Department of Gastroenterology and Foundation for Research in Digestive Diseases (FIENAD). Hospital Universitario de Santiago de Compostela. A Coruña, Spain. 2Institute of Medicine. Sahlgrenska Academy. University of Gothenburg. Gothenburg, Sweden

ABSTRACT

Differential diagnosis of solid pancreatic lesions remains as an important clinical challenge, mainly for the differentiation between mass forming chronic pancreatitis, autoimmune pancreatitis and pancreatic adenocarcinoma. Endoscopic ultrasound (EUS), computed tomography (CT) and magnetic resonance imaging (MRI) can all provide valuable and complementary information in this setting. Among them, EUS has the unique ability to obtain specimens for histopathological diagnosis and can therefore play a crucial role in the evaluation patients with inconclusive findings on initial examinations. Nowadays, new developed techniques associated to EUS, like elastography and contrast enhancement, have shown promising results for the differential diagnosis of these pancreatic lesions.

Key words: Endoscopic ultrasound. CT scan. MRI. Pancreatic tumors.

INTRODUCTION

Differential diagnosis of solid pancreatic masses remains a challenge, despite recent advances in different diagnostic procedures. In this article, the role of endoscopic ultrasound (EUS) including EUS-guided FNA, elastography and contrast enhancement will be reviewed in relation to computer tomography (CT), magnetic resonance tomography (MRT) and magnetic resonance cholangiopancreatography (MRCP). Differential diagnosis between malignant lesions and mass-forming chronic pancreatitis or focal autoimmune pancreatitis will be discussed. Tumor staging and evaluation of resectability of these pancreatic lesions will not be evaluated. Other imaging techniques, like PET-scan or octreoscan will not be analyze, because their usefulness in this context is unclear.

Differential diagnosis between malignant pancreatic lesions (pancreatic cancer, pancreatic metastasis) and mass-forming chronic pancreatitis

CT scan is the most widely spread imaging modality for evaluation of pancreatic solid masses and considered as the most comprehensive tool for diagnosis and surgical staging of pancreatic malignancies (1). CT technology has significantly advanced over the last years, multidetector helical CT scan allows for very thin sliced cuts, providing a higher image resolution and faster image acquisition (Fig. 1). Oblique cuts, curved reformation images, and volume 3D

Fig. 1. Multidetector CT scan showing a pancreatic mass at pancreatic head, corresponding to a pancreatic adenocarcinoma.
reconstructed images can be obtained by post imaging processing. Despite these advances, differential diagnosis between mass-forming chronic pancreatitis, ductal adenocarcinoma, and autoimmune pancreatitis based on only CT image can be challenging (2,3). The vast majority of solid malignancies of the pancreas are hypovascularized and will therefore present low attenuation on contrast enhanced CT. However, isoattenuating pancreatic adenocarcinomas exist, making diagnosis by CT much more difficult. Prokesh et al. reported that 11% of solid pancreatic malignancies were isoattenuating on CT (4). In such cases, secondary signs like dilatation of the pancreatic and/or biliary duct may raise the suspicion of a compressing malignant process. Pancreatic adenocarcinomas area rarely hyper-enhanced (this is mainly associated to neuroendocrine tumors). Differential diagnosis between chronic pancreatitis and pancreatic adenocarcinoma by triple-phase helical CT scan was recently investigated in a study on 42 patients with chronic pancreatitis and 85 patients with pancreatic adenocarcinoma by Yamada et al. (5). protocol with scan delays of 40, 70, and 150 s; and 370 mg I/mL of contrast was used. Mean contrast enhancement in normal pancreatic tissue peaked during the first phase (early-washout pattern) while that of chronic pancreatitis peaked during the second phase (delayed-washout pattern), and that of pancreatic adenocarcinoma gradually increased in all phases. Diagnostic indices for pancreatic adenocarcinoma were 94.1% for sensitivity, 83% for specificity, and 90.4% for accuracy, when differentiation between chronic pancreatitis and pancreatic adenocarcinoma was performed based on time-attenuation curve patterns.

**MRI** can be useful in the differentiation of pancreatic solid masses but is considered less sensitive than CT and EUS for detection and evaluation of solid pancreatic tumors (6). Pancreatic adenocarcinoma appears hypo intense on T1-weighted images both pre and post contrast injection (Fig. 2). A meta-analysis by Bipat et al. (7), showed MRI to be less sensitive than CT scan (84 vs. 91%) in the detection of pancreatic cancer. The administration of secretin during MRCP can be useful by enhancing the image of the main pancreatic duct, demonstrating dilated side-branches and providing information on pancreatic function (8). Another important advantage of MRI is that it is superior to other imaging modalities in visualizing tumors within areas of pancreatic inflammation (9).

**EUS** can produce high-resolution images of the pancreas and is considered as one of the most accurate methods for the diagnosis and staging of inflammatory, cystic and neoplastic diseases of the pancreas (10-12) (Fig. 3). Drawbacks include difficulty in differentiation between pancreatic cancer and focal pancreatitis based on B-mode images, particularly in cases of advanced chronic pancreatitis, and the fact that the method is highly operator dependent. Despite the high-resolution images produced by conventional EUS, the accuracy in differentiation between benign inflammatory masses and malignant tumors of the pancreas is not higher than 75% (13-19). This is partly due to the fact that changes like internal and/or peripheral calcifications similar to what is observed in advanced chronic pancreatitis are present in a proportion of pancreatic malignancies. EUS guided fine needle aspiration (EUS-FNA) has the ability to overcome this problem in many cases.

The role of **EUS-FNA** in the diagnosis of solid pancreatic tumors has been evaluated in several, well-designed studies. Reported sensitivity and accuracy for malignancy ranges from 75 to 92% and from 79 to 92%, respectively (19-33). This accuracy may be even higher using on-site evaluation of the sample by an experienced pathologist (34). Furthermore, in addition to differentiation between benign and malignant lesions, EUS-FNA can also establish the final
diagnostic sensitivity, specificity and overall accuracy in were no differences in terms of specificity (100 and pancreatic adenocarcinoma (72.7 in the group of patients with concurrent chronic pancreatitis the differential diagnosis between inflammatory process and overall accuracy (91.5 patients with chronic pancreatitis, EU S-F N A increased A rdengh et al. (37) including 69 pancreatic masses in compared to those without (73.9 vs. 91.3%; p = 0.02). There were no differences in terms of specificity (100 vs. 93.8%), and overall accuracy (91.5 vs. 91.4%). In a study by Ardengh et al. (37) including 69 pancreatic masses in patients with chronic pancreatitis, EU S-F N A increased diagnostic sensitivity, specificity and overall accuracy in the differential diagnosis between inflammatory process and pancreatic adenocarcinoma (72.7 vs. 63.6%; 100 vs. 75.9%; 95.7 vs. 73.9%; respectively) compared to EU S alone. Takahashi et al. (39) evaluated 62 patients with pancreatic cancer and 15 with focal pancreatitis, reporting sensitivity, specificity, overall accuracy, positive predictive value, and negative predictive value of cytopathology diagnosis of 82, 100, 86, 100, and 58%, respectively. They also observed K-ras point mutations in 74% of pancreatic cancers and 0% of focal pancreatitis lesions.

Certain drawbacks of EU S-F N A need to be emphasized. The procedure is difficult to perform in certain cases, owing to vessel interposition, duodenal stenosis and tumor hardness, particularly in chronic pancreatitis, which hampers the overall accuracy of the procedure. In some occasions EU S-F N A samples cannot be interpreted due to bleeding or non-cellular samples. A systematic review of 53 studies estimated the negative predictive value of EU S-F N A in the diagnosis of pancreatic adenocarcinoma to 60-70% (40). Hence, a new puncture seems mandatory in order to exclude malignancy in cases where the first EUS-F N A has been benign (41). Given the high accuracy in the evaluation of pancreatic tumors, Eloubeidi et al. concluded in a recent study that routine EUS-F N A for the differential diagnosis of solid pancreatic masses can be recommended (42).

In order to optimize tissue retrieval of EUS-F N A, various EU S-guided techniques have been explored, including FNA and Tru-Cut needles, with variable success and complication rates (43-46). Of particular interest is the Quick-Core® needle, designed to operate through an echoendoscope. EU S-guided use of Quick-Core® needle has demonstrated that histological samples representative of the target organs can be obtained safely (47,48). However, there are certain drawbacks with the Quick-Core® needle that restrict its use in clinical practice. Most importantly, its diagnostic yield is strongly limited for lesions located in pancreatic head due to mechanical friction of the needle firing mechanism ensuing from the bended scope position (49-52). In this setting a novel needle have been designed (Procure™ histology needle) to overcome trucut needle limitations (mainly in the second portion of the duodenum) and initial preliminary results are promising and it appears that may help solve this problem, allowing a histological evaluation with an overall accuracy of 85.9% (89.4% in pancreatic solid lesions) (53). There are also other needles in the market (O lympus EZShot2 NA-230H-8022), designed to obtain histological samples, but its clinical usefulness and safety are still under evaluation.

E US elastography is a noninvasive technique that measures elasticity in real time by registration of differences in distortion of the EU S image after application of slight pressure by the EU S probe (Figs. 4 and 5). Many different pathological processes, including inflammation, fibrosis and cancer, can alter tissue elasticity that will result in distinct elastographic appearance. The first studies published on EU S elastography were based on qualitative elastography evaluation, using a hue-color scale representing different degrees of tissue elasticity. Giovannini et al. (54) analyzed
24 pancreatic masses using a scoring system based on different color patterns in EUS elastography images. Sensitivity and a specificity of 100 and 67% respectively were observed in the differentiation between benign and malignant pancreatic masses. In a multicenter study (55), including 121 pancreatic masses, sensitivity and specificity of EUS elastography to differentiate benign from malignant pancreatic lesions were 92.3 and 80.0%, respectively, compared to 92.3 and 68.9%, respectively, for the conventional B-mode images. The interobserver agreement was substantial (kappa score = 0.785). Another paper published by Iglesias-García et al. (56), analyzed 130 patients with solid pancreatic masses. Malignancy could be diagnosed by qualitative EUS-elastography using color patterns with a sensitivity, specificity, positive and negative predictive values, and overall accuracy of 100, 85.5, 90.7, 100 and 94.0%, respectively. However, substantially lower diagnostic performance by qualitative elastography has been reported. Hirsche et al. (57), presented their results on 70 patients with unclassified solid pancreatic lesions, and found that they could only perform an adequate evaluation in 56% of patients, and that EUS-elastography predicted the nature of pancreatic lesions with poor diagnostic sensitivity (41%), specificity (53%) and accuracy (45%). Recently quantitative EUS elastography has been developed in an attempt to make the elastography interpretation less subjective. Quantitative elastography renders a numeric result, either as mean value of hues in a selected area (mean hue histogram) or as a ratio of elasticity in the target area over soft reference tissue (strain ratio). Iglesias-García et al. (14), have evaluated strain ratio in 86 consecutive patients with solid pancreatic masses (49 adenocarcinomas, 27 inflammatory masses, 6 malignant neuroendocrine tumors, 2 metastatic oat cell lung cancers, 1 pancreatic lymphoma, and 1 pancreatic solid pseudopapillary tumor) and 20 controls. The strain ratio was significantly higher among patients with malignant pancreatic tumors compared to those with inflammatory masses. Normal pancreatic tissue showed a mean strain ratio of 1.68 (95%CI: 1.59-1.78). Inflammatory masses presented a strain ratio (mean 3.28; 95%CI: 2.61-3.96) significantly higher than that of the normal pancreas (p < 0.001), but lower than that of pancreatic adenocarcinoma (mean 18.12; 95%CI: 16.03-20.21) (p < 0.001). The highest strain ratio was found among endocrine tumors (mean 52.34; 95%CI: 33.96-70.71). The sensitivity and specificity of the strain ratio for detecting pancreatic malignancies using a cutoff value of 6.04 were 100% and 92.9%, respectively, exceeding the accuracy obtained with qualitative elastography. Saftoiu et al. (58) evaluated the usefulness of the hue-histograms in a similar setting. Based on a cutoff of 175 for the mean hue histogram value, the sensitivity, specificity, and accuracy of differentiation of benign and malignant masses were 91.4, 87.9, and 89.7%, respectively. The positive and negative predictive values were 88.9 and 90.6%, respectively. The same methodology and cut-off value was used in a subsequent multicenter study including 258 patients. A sensitivity of 93.4%, a specificity of 66.0%, a positive predictive value of 92.5%, a negative predictive value of 68.9%, and an overall accuracy of 85.4% for the mean hue histogram in the detection of malignancy were observed (59).

Administration of contrast agents is another way to improve EUS based diagnosis of solid pancreatic tumors. Initial studies using Levovist®, Albunex and FS 069 Optison as contrast agents indicated that contrast enhanced EUS could be useful to detect malignant vascular infiltration and demonstrated that the hyper vascular aspect of neuroendocrine tumors and the hypo vascular aspect of pancreatic adenocarcinoma could be readily demonstrated (60-64). Modern contrast enhanced EUS relies on a dedicated contrast harmonic echo (CHE–EUS) technique that detects signals from micro bubbles delivered by new contrast agents like Sonovue® in vessels with very slow flow without the burden of Doppler-related artifacts. Fusaroli et al. investigated 90 patients with solid pancreatic lesions by CEH-EUS, using Sonovue® as contrast agent (65). The finding of a hypo-enhancing mass with an inhomogeneous pattern diagnosed pancreatic adenocarcinoma with a sensitivity of 96% and an accuracy of 82%. The study also indicated that this CEH-EUS pattern diagnosed malignancy more accurately than the finding of a hypoechoic mass on standard EUS (p < 0.0001). Hyper-enhancement specifically excluded adenocarcinoma (98%), although sensitivity was low (39%). An interesting observation was that CHE–EUS detected small lesions in 7 patients where conventional EUS findings were inconclusive due to biliary stents or chronic pancreatitis. In a recent study by Napoleon et al. (66) on 35 patients with solid pancreatic lesions, the finding of a hypo-enhanced lesion was able to detect malignancy with a sensitivity, specificity and accuracy of 89, 88, and 88.5%, respectively. Four out of five patients with adenocarcinomas with false-negative results at EUS-FNA had a hypo-enhanced appearance on CEH-EUS in this series. Seicean et al. (67) investigated the possibility to use quantitative CEH-EUS data in the differential diagnosis between pancreatic cancer and chronic pancreatitis. A hypo-enhanced pattern was the most common finding both in with pancreatic adenocarcinoma (14/15 cases) and in mass forming chronic pancreatitis (10/12 cases). However, an index of contrast uptake ratio was calculated and this was significantly lower in adenocarcinoma compared to cases with mass-forming chronic pancreatitis. A cut-off uptake ratio index value of 0.17 for diagnosing adenocarcinoma corresponded to an AUC of 0.86 (95%CI: 0.67-1.00) with a sensitivity of 80%, a specificity of 91.7%, a positive predictive value of 92.8%, and a negative predictive value of 78%. Generally, differences in histology, such as histological differentiation grade, amount of fibrosis and obliteration of blood vessels in the tumor, may be associated with differences in enhancement behavior.

**Differential diagnosis of focal autoimmune pancreatitis**

Autoimmune pancreatitis is a recently described but today globally acknowledged entity (68-71). The clinical
Autoimmune pancreatitis is associated with elevated titers of IgG, IgG4, and antinuclear antibody (81,82). However, false positive elevations have been observed in all of these serological markers in patients with other pancreatic disorders, including pancreatic cancer. Gahzaale et al. have investigated the role of serum IgG4 measurement in a study on 510 patients (45 with autoimmune pancreatitis, 135 with pancreatic cancer, 62 without pancreatic disease and 268 with other pancreatic diseases). A sensitivity, specificity and positive predictive value of 76, 93 and 36% for the diagnosis of autoimmune pancreatitis was found when the upper normal limit (140 mg/dL) was used as cutoff value. Corresponding diagnostic performance values were 53, 99 and 75%, respectively, if the cutoff value was elevated to two times the upper normal limit (280 mg/dL) (77). Autoimmune pancreatitis is a systemic disease and involvement of other organs is another finding that can support the diagnosis. Other organ involvement may be diagnosed by histology, imaging (proximal bile duct stricture, retroperitoneal fibrosis) or clinical examination (salivary gland enlargement). EUS-guided biopsies using large core biopsy needles can be used to obtain histological specimens for the diagnosis of autoimmune pancreatitis. Demonstration of the typical lymphoplasmacytic infiltrate has been proven to be possible and safe with EUS guided biopsies using the Tru-Cut needle (Quick-Core®) (83,84). However, histological diagnosis of autoimmune pancreatitis is extremely difficult (even using Tru-cut or Procore™ needle) and diagnosis with EUS-FNA cytology needles is almost impossible. Response to steroid treatment is a final criterion that can be used to differentiate between autoimmune pancreatitis and pancreatic cancer. A treatment trial is usually performed by oral administration of prednisone 0.5 mg/kg during two weeks followed by reassessment of imaging and CA19-9 (85). An improvement of imaging abnormalities, including biliary strictures and pancreatic enlargement is required for confirmation of the diagnosis of autoimmune pancreatitis. Moon et al. (85) studied the effect of steroid challenge in 22 patients with a clinical suspicion of autoimmune pancreatitis but with imaging findings that could not conclusively differentiate between pancreatic cancer and autoimmune pancreatitis. Steroid treatment led to radiological improvement in all patients with a final diagnosis of autoimmune pancreatitis (n = 15) and no response in patients where the final diagnosis was pancreatic cancer (n = 7). International consensus guidelines for the diagnosis of autoimmune pancreatitis have been recently published by the International Association of Pancreatology (80).

**CONCLUSIONS**

EUS, CT and MRI can all provide valuable and complementary information in the differential diagnosis between mass forming chronic pancreatitis, autoimmune pancreatitis and pancreatic adenocarcinoma. EUS has the unique ability to obtain specimens for histopathological diagnosis and can therefore play a crucial role in the evaluation patients with inconclusive findings on initial examinations. EUS guided elastography and the uses of contrast agents together with harmonic echo are also useful in this setting.

**REFERENCES**


